Our Products

ESOMEPRAZOLE 40MG TABLETS

Amoxicillin 1g, Clarithromycin 500 mg, Esomeprazole 20 mg.

First Line Treatment Regimen for eradication of Helicobacter pylori infection and prevention of duodenal

ulceration due to H. pylori

Administer (Amoxicillin 1g, Clarithromycin 500 mg, Esomeprazole 20 mg) BD for 14 days

ESOMEPRAZOLE 20MG TABLETS

Name of the medicinal product: 

Esomeprazole 20mg Tablets

Qualitative and quantitative composition:

Each enteric coated tablet contains Esomeprazole Trihydrate BP equivalent to Esomeprazole 20mg.

Therapeutic indications

Adults: Esomeprazole 20mg tablets are indicated in adults for:

• Gastro-oesophageal Reflux Disease (GORD)
• treatment of erosive reflux oesophagitis
• long-term management of patients with healed oesophagitis to prevent relapse – symptomatic treatment of gastro-oesophageal reflux disease (GORD) In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori and
• healing of Helicobacter pylori associated duodenal ulcer and
• prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers Patients requiring continued NSAID therapy
• healing of gastric ulcers associated with NSAID therapy.
• prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk. Treatment of Zollinger Ellison Syndrome Esomeprazole 20mg tablets are indicated in adolescents from the age of 12 years for: Gastro-oesophageal Reflux Disease (GORD)
• treatment of erosive reflux oesophagitis
• long-term management of patients with healed oesophagitis to prevent relapse – symptomatic treatment of gastro-oesophageal reflux disease (GORD) In combination with antibiotics in treatment of duodenal ulcer caused by Helicobacter pylori.

Name of the medicinal product :

• Simethicone 25mg/5ml
• Magnesium Hydroxide 200mg/5ml
• Dried Aluminium Hydroxide Gel 225mg/5ml
• Also contains sorbitol.

Pharmaceutical form:

Therapeutic indications:

1. Dyspepsia.
2. Heartburn.
3. Flatulence.
4. Hyperacidity

Posology and method of administration For oral administration:

Contraindications:

Name of the medicinal product:

Qualitative and quantitative composition:

Therapeutic indications:

• Acute streptococcal tonsillitis and pharyngitis.
• Acute bacterial sinusitis.
• Acute otitis media.
• Acute exacerbations of chronic bronchitis.
• Cystitis – Pyelonephritis.
• Uncomplicated skin and soft tissue infections.
• Treatment of early Lyme disease.
• Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Posology and method of administration:

AMOXICILLIN TRIHYDRATE EQUIVALENT TO 875 MG AMOXICILLIN AND POTASSIUM CLAVULANATE EQUIVALENT TO 125 MG OF CLAVULANIC ACID TABLETS

Name of the medicinal product:

Qualitative and quantitative composition:

Therapeutic indications:

• Acute bacterial sinusitis
• Acute exacerbations of chronic bronchitis
• Community-acquired pneumonia
• Complicated skin and soft tissue infections For the above-mentioned infections Levofloxacin 500mg Film-coated Tablets should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections.
• Pyelonephritis and complicated urinary tract infections.
• Chronic bacterial prostatitis
• Uncomplicated cystitis
• Inhalation Anthrax: post exposure prophylaxis and curative treatment
• Levofloxacin 500mg Film-coated Tablets may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous levofloxacin. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Posology and method of administration:

Name of the medicinal product:

Therapeutic indications

• Lower respiratory tract infections for example: acute and chronic bronchitis, and pneumonia.
• Upper respiratory tract infections for example: sinusitis and pharyngitis.
• Clarithromycin is appropriate for initial therapy in community acquired respiratory infections and has been shown to be active in vitro against common and atypical respiratory pathogens as listed in the microbiology section.
• Clarithromycin is also indicated in skin and soft tissue infections of mild to moderate severity.
• Clarithromycin in the presence of acid suppression effected by omeprazole or lansoprazole is also indicated for the eradication of H. pylori in patients with duodenal ulcers. Clarithromycin is usually active against the following organisms in vitro:
• Gram-positive Bacteria: Staphylococcus aureus (methicillin susceptible); Streptococcus pyogenes (Group A beta-hemolytic streptococci); alpha-hemolytic streptococci (viridans group); Streptococcus (Diplococcus) pneumoniae; Streptococcus agalactiae; Listeria monocytogenes.
• Gram-negative Bacteria: Haemophilus influenzae; Haemophilus parainfluenzae; Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae; Legionella pneumophila; Bordetella pertussis; Helicobacter pylori; Campylobacter jejuni.
• Mycoplasma: Mycoplasma pneumoniae; Ureaplasma urealyticum.
• Other Organisms: Chlamydia trachomatis; Mycobacterium avium; Mycobacterium leprae
• Anaerobes: Macrolide-susceptible Bacteroides fragilis; Clostridium perfringens; Peptococcus species; Peptostreptococcus species; Propionibacterium acnes.
• Clarithromycin has bactericidal activity against several bacterial strains. The organisms include Haemophilus influenzae; Streptococcus pneumoniae; Streptococcus pyogenes; Streptococcus agalactiae; Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae; H. pylori and Campylobacter spp.

Name of the medicinal product:

Qualitative and quantitative composition:

Therapeutic indications:

• Upper Respiratory Tract Infections (URTI): e.g. otitis media; and other URTI where the causative organism is known or suspected to be resistant to other commonly used antibiotics, or where treatment failure may carry significant risk.
• Lower Respiratory Tract Infection: e.g. bronchitis.
• Urinary Tract Infections: e.g. cystitis, cystourethritis, uncomplicated pyelonephritis. Clinical efficacy has been demonstrated in infections caused by commonly occurring pathogens including Streptococcus pneumoniae, Streptococcus pyogenes, Escherichia coli, Proteus mirabilis, Kliebsiella species, Haemophilus influenzae (beta-lactamase positive and negative), Branhamella catarrhalis (beta-lactamase positive and negative) and Enterobacter species. Cefixime is highly stable in the presence of beta-lactamase enzymes. Most strains of enterococci (Streptococcus faecalis, group D Streptococci) and Staphylococci (including coagulase positive and negative strains and methicillin-resistant strains) are resistant to Cefixime. In addition, most strains of Pseudomonas, Bacteriodes fragalis, Listeria monocytogenes and Clostridia are resistant to Cefixime.

Name of the medicinal product:

Qualitative and quantitative composition:

Pharmaceutical form:

Therapeutic indications:

• Acute bacterial sinusitis (adequately diagnosed)
•  Acute bacterial otitis media (adequately diagnosed)
• Pharyngitis, tonsillitis
• Acute exacerbation of chronic bronchitis (adequately diagnosed)
• Mild to moderately severe community acquired pneumonia
• Infections of the skin and soft tissues of mild to moderate severity e.g. folliculitis, cellulitis, erysipelas.
• Uncomplicated Chlamydia trachomatis urethritis and cervicitis Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Composition

Pharmaceutical Form.

Therapeutic Indications

Posology and Method of Administration

• For topical administration.
• Adults, Elderly and Children:
• Wash affected areas and leave for 3-5 minutes before rinsing.

Contraindications Known hypersensitivity to ketoconazole, zinc pyrithione or any of the excipients.

TERBINAFINE HYDROCHLORIDE 1% CREAM

• In onychomycoses, Griseofuvin has done its part for so many years but relapse rates, high incidence of liver toxicity and limited spectrum of antifungal activity make terbinafine, Oncosil, the preferred treatment of choice. A continuous administration regimen of 250 mg, 6 weeks for fingernail and 12 weeks for toenail onychomycosis has a 76% mycological and clinical cure rate higher than itraconazole.
• According to a meta-analysis by Gupta and Foley et al (2015), Oncosil 1% cream is considered first line in treatment of Pityariasis versicolor on a twice daily dosing with a 90% mycological cure rate on day 14 and 100% complete cure rate on the 28th day. Topical Oncosil, for Pityriasis versicolor can be administered with the first line systemic antifungal, itraconazole (Itranox) 200 mg for 7 days to boost cure rates and treat stubborn tinea versicolor with a mycological cure of 90% (Kose et al, 2002) and a complete cure rate of 87% (Galimberti et al, 1987).
• In tinea corporis and pedis, a period of 4 weeks of 250 mg/day PO in single dose or divided every 12 hours will achieve cure rates and Oncosil is first line.”

• In onychomycoses, Griseofuvin has done its part for so many years but relapse rates, high incidence of liver toxicity and limited spectrum of antifungal activity make terbinafine, Oncosil, the preferred treatment of choice. A continuous administration regimen of 250 mg, 6 weeks for fingernail and 12 weeks for toenail onychomycosis has a 76% mycological and clinical cure rate higher than itraconazole.
• According to a meta-analysis by Gupta and Foley et al (2015), Oncosil 1% cream is considered first line in treatment of Pityariasis versicolor on a twice daily dosing with a 90% mycological cure rate on day 14 and 100% complete cure rate on the 28th day. Topical Oncosil, for Pityriasis versicolor can be administered with the first line systemic antifungal, itraconazole (Itranox) 200 mg for 7 days to boost cure rates and treat stubborn tinea versicolor with a mycological cure of 90% (Kose et al, 2002) and a complete cure rate of 87% (Galimberti et al, 1987).
• In tinea corporis and pedis, a period of 4 weeks of 250 mg/day PO in single dose or divided every 12 hours will achieve cure rates and Oncosil is first line.”

Qualitative and quantitative composition

• Each hard gelatin capsule contains Itraconazole 100mg BP as pellets

Therapeutic indications

• Vulvovaginal candidiasis,
• Oral candidiasis
• Dermatophytoses caused by organisms susceptible to itraconazole (Trichophyton spp., Microsporum spp., Epidermophyton floccosum) e.g. tinea pedis, tinea cruris, tinea corporis, tinea manuum,
• Pityriasis versicolor,
• Onychomycoses caused by dermatophytes and/or yeasts,
• Systemic candidiasis,
• Cryptococcal infections (including cryptococcal meningitis). In immunosuppressed patients suffering from cryptococcosis and in patients with cryptococcosis of the CNS Itraconazole is indicated only if the usually recommended initial therapy seems to be inappropriate or ineffective
• Histoplasmosis.
• Aspergillosis. Itraconazole can be used to treat patients suffering from invasive aspergillosis who were found to be refractory or intolerant to Amphotericin B
• Maintenance therapy in AIDS patients to prevent relapse of underlying fungal infection who were found to be refractory or intolerant to first-line systemic anti-fungal therapy is inappropriate or has proved ineffective. Due to PK properties, orally administered itraconazole (capsules) should not be used as the initial treatment in patients with severe life-threatening forms of systemic mycoses. Oral forms should be used as a continuation therapy, after initial treatment with i.v. itraconazole. Consideration should be given to official guidance regarding the appropriate use of antifungal agents.

Fluconazole is indicated in adults for the prophylaxis of:

• Relapse of cryptococcal meningitis in patients with high risk of recurrence.
• Relapse of oropharyngeal or esophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse.
• To reduce the incidence of recurrent vaginal candidiasis (4 or more episodes a year).
• Prophylaxis of candida infections in patients with prolonged neutropenia (such as patients with hematological malignancies receiving chemotherapy or patients receiving Hematopoietic Stem Cell Transplantation.

Dosage and Administration Posology

Fluconazole is indicated in adults for the prophylaxis of:

• Relapse of cryptococcal meningitis in patients with high risk of recurrence.
• Relapse of oropharyngeal or esophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse.
• To reduce the incidence of recurrent vaginal candidiasis (4 or more episodes a year).
• Prophylaxis of candida infections in patients with prolonged neutropenia (such as patients with hematological malignancies receiving chemotherapy or patients receiving Hematopoietic Stem Cell Transplantation.

Dosage and Administration Posology

ARTESUNATE 100MG; MEFLOQUINE HYDROCHLORIDE BP (EQUIVALENT TO MEFLOQUINE BASE 200MG) TABLETS

Name of the medicinal product:

Qualitative and quantitative composition:

Therapeutic indications:

Posology and method of administration:

DIHYDROARTEMESININ 80MG, PIPERAQUINE PHOSPHATE 640MG FOR ORAL SUSPENSION

Name of the medicinal product:

Composition:

Description:

Pharmacology

Indications:

• Arteether is an anti-malarial used for the treatment of severe falciparum malaria active against P. falciparum strains that are resistant to chloroquine, mefloquine, halofantrine, quinine, pyrimethamine, cycloguanil and amodiaquine.
• Alpha/beta arteether is also used for the treatment of uncomplicated falciparum malaria.

Dosage and Administration:

Contraindications

ARTEMETHER 180MG, LUMEFANTRINE 1080MG FOR ORAL SUSPENSION

Name of the medicinal product:

Qualitative and quantitative composition:

Therapeutic indications:

Posology and method of administration:

Treatment and stand-by emergency treatment:

Name of the medicinal product:

Qualitative and quantitative composition:

Therapeutic Indications:

• Osteoarthritis and rheumatoid arthritis.
• Pain relief in osteoarthritis
• Rehabilitation of damaged cartilage

Dosage and Directions for Use:

Contraindications

Qualitative and quantitative composition

Therapeutic Indications:

• Soft tissue injuries with spasms and inflammation \
• Neck, shoulder and back pain
• Menstrual pain
• Tendonitis
• Tenosynovitis
• Bursitis
• Muscle pain
• Relief of the pain of osteoarthritis of knees and hands
• Headache
• Ear Pain

PARACETAMOL BP 450MG, CAFFEINE BP 50MG, CODEINE PHOSPHATE BP 10MG, DOXYLAMINE SUCCINATE USP 5MG TABLETS

CHLORZOXAZONE 300MG

Qualitative and quantitative composition

Each tablet contains Chlorzoxazone USP 250mg and Paracetamol BP 325mg.

Therapeutic Indications:

Myocor is indicated for the relief of severe skeletal spasm and pain associated with medical problems such as:

• Sprains and strains
• Myalgia
• Tension headaches
• Traumatic muscle injuries
• Low back pain
• Fibrositis
• Cervical root and disc syndromes

Contraindications

Hypersensitivity to the chlorzoxazone and paracetamol or to any of the excipients.